Drug Profile

BEBT 701

Alternative Names: BEBT-701

Latest Information Update: 10 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BeBetter Med
Class Antihyperlipidaemics; Antihypertensives; Small interfering RNA
Mechanism of Action Angiotensinogen expression inhibitors; PCSK9 protein expression inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Hyperlipidaemia; Hypertension

Most Recent Events

19 Dec 2024 BEBT 701 is available for licensing as of 19 Dec 2024. http://www.bebettermed.com/goods-2-view.html
19 Dec 2024 Preclinical trials in Hyperlipidemia in China (Parenteral) prior to December 2024
19 Dec 2024 Preclinical trials in Hypertension in China (Parenteral) prior to December 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com